Analysts See $-0.11 EPS for Galectin Therapeutics, Inc. (GALT)

March 15, 2018 - By Marie Mckinney

 Analysts See $ 0.11 EPS for Galectin Therapeutics, Inc. (GALT)
Investors sentiment decreased to 0.67 in 2017 Q3. Its down 1.22, from 1.89 in 2017Q2. It dropped, as 7 investors sold Galectin Therapeutics, Inc. shares while 8 reduced holdings. 4 funds opened positions while 6 raised stakes. 3.22 million shares or 4.39% less from 3.37 million shares in 2017Q2 were reported.
Schwab Charles Invest Management holds 21,400 shares. Courage Management has 130,000 shares. Tiedemann Wealth Ltd Liability Company holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 15,000 shares. Da Davidson reported 690,960 shares. Northern Corporation reported 80,739 shares. Moreover, Gru One Trading Lp has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 23,052 shares. Thrivent For Lutherans has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 6,000 shares. Wells Fargo Mn owns 11,882 shares or 0% of their US portfolio. 118,921 were reported by Us National Bank & Trust De. Riggs Asset Managment stated it has 1,000 shares or 0% of all its holdings. Norris Perne French Llp Mi has 0.01% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 30,500 shares. Deutsche Retail Bank Ag invested in 0% or 2 shares. 54,600 were reported by Cutter Brokerage. Guggenheim Cap Ltd, Illinois-based fund reported 11,688 shares. Tci Wealth Advsrs invested in 0% or 300 shares.

Since January 25, 2018, it had 2 buys, and 2 selling transactions for $2.64 million activity. The insider CZIRR JAMES C sold $1.33M. 10X Fund – L.P. also sold $1.33M worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) shares.

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.11 EPS on March, 29 before the open.They anticipate $0.02 EPS change or 15.38 % from last quarter’s $-0.13 EPS. After having $-0.13 EPS previously, Galectin Therapeutics, Inc.’s analysts see -15.38 % EPS growth. The stock decreased 8.29% or $0.43 during the last trading session, reaching $4.76. About 376,023 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 62.09% since March 15, 2017 and is uptrending. It has outperformed by 45.39% the S&P500.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. The rating was reinitiated by H.C. Wainwright on Monday, March 28 with “Buy”. H.C. Wainwright initiated the stock with “Buy” rating in Monday, September 21 report. Roth Capital maintained Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Thursday, January 4. Roth Capital has “Buy” rating and $8.0 target. TH Capital downgraded the stock to “Sell” rating in Wednesday, September 28 report. H.C. Wainwright upgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Thursday, March 30. H.C. Wainwright has “Buy” rating and $3.50 target. As per Thursday, December 7, the company rating was maintained by Roth Capital. The firm has “Buy” rating given on Wednesday, June 14 by H.C. Wainwright. The rating was downgraded by Roth Capital on Wednesday, September 28 to “Sell”. FBR Capital downgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Monday, October 3. FBR Capital has “Mkt Perform” rating and $2 target. The rating was downgraded by H.C. Wainwright to “Neutral” on Thursday, September 29.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $172.02 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “Galectin Therapeutics to Present at Two International Conferences in March” on March 09, 2018, also with their article: “Update On Galectin Therapeutics’ Potential Entry Into Cancer Market” published on February 15, 2018, published: “Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial” on December 05, 2017. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: and their article: “Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting …” published on March 05, 2018 as well as‘s news article titled: “Galectin Therapeutics Granted Patents in China and Japan that Support NASH and …” with publication date: January 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.